within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DC12_Cefminox;

model Cefminox
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.5444444444444444e-06,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.013900000000000001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.009300000000000001,
    k12 = 3.0833333333333336e-06,
    k21 = 3.0833333333333336e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cefminox</td></tr><tr><td>ATC code:</td><td>J01DC12</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>13.9</td><td>L</td></tr>
    <tr><td>clearance:</td><td>5.56</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cefminox is a second-generation cephalosporin antibiotic, used primarily in the treatment of bacterial infections, particularly those caused by Gram-negative and some Gram-positive organisms. It has been mainly used in East Asia and is not widely approved or used in Western countries today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single intravenous infusion; parameters may vary in patients with renal impairment.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01DC12 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cefminox;
